Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva Continues Divestitures To Close Allergan Deal With Sale To Impax

Executive Summary

Impax will gain 15 approved generics and three pipeline assets, which will help address offset lower revenues of two of its existing top-sellers.

You may also be interested in...



Consolidation in Generics Sector As Impax Merges With Amneal

The deal will create the fifth-largest generics company in the US with one of the largest pipelines, with about 150 pending ANDAs and 165 projects in active stages of development.

Consolidation in Generics Sector As Impax Merges With Amneal

The deal will create the fifth-largest generics company in the US with one of the largest pipelines, with about 150 pending ANDAs and 165 projects in active stages of development.

Teva Embarks On New Phase With FTC Clearance Of Allergan Generics

Teva said the deal will close the first week of August, after agreeing to sell assets related to 79 pharmaceutical products to gain FTC clearance.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC065478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel